Excited to share our latest review by our postdoc @flurinab on expanding perspectives of PARP1 and PARP inhibitors in cancer therapy. Great work! You can check it out here: https://t.co/hjOHhPBgD7
Excited to share our latest research on the role of PARP14 ADP-ribosylation of p62, now available on bioRxiv! Kudos to David and the team for their hard work. Check it out! https://t.co/zXCRxKfTk1 #Science#bioRxiv#PARP14#ADPribosylation
Congrats to Patrick and his colleagues for the latest publication in PNAS! The paper shows the role of PARP7 in FRA1-positive cancers and explains how specific PARP7 inhibitors can help to fight lung cancer. Well done!🎉
https://t.co/mpM3zDxwU2
Time to celebrate🥳🎉! We are very proud of our Post-Doctoral fellow Lorenza and her co-authors for getting their paper published in Cancer Research (@AACR)
Read more on how combinatorial treatment with PARP and MAPK inhibitors mitigates drug resistance in advanced melanoma.
Join us for the FEBS Advanced Lecture Course on Cellular Stress and ADP-ribosylation at the seaside of Naples! 🏖️
Covering a wide range of topics, this 5-day course offers valuable insights from top experts, flash poster presentations, and networking opportunities.
Very proud of our PhD Candidate Anka and her co-authors for getting their paper published in @NAR_Open ✨ Time to celebrate 🥂
Read more on the interplay between the mitochondrial and nuclear NAD+ pools here: https://t.co/sg7tujyKPM
💫🎉 Congrats to @lutherfabian_, Rory Doolan and @MariolinaBruno for best talk, best flash talk and best poster at the 2nd #SYIS Annual Symposium!!
💫🎉 Congratulations to the winners of the @EFIS_Immunology travel grant.
📢The second #SYIS Symposium will take place on August 23rd at Inselspital in Bern. We are putting together an exciting program for you including sessions on Tumor and Mucosal #Immunology. Stay tuned!!